Last reviewed · How we verify

NCT05996289: VARIOP

Inter-observer Variability in the Segmentation of Prostate Tumour Lesions Using Multiparametric MRI (VARIOP)

Status unknown Last updated 18 August 2023
What this trial tests

trial in Prostate Cancer in 70 participants. Status unknown.

Timeline
1 August 2023
Primary endpoint
1 July 2024
1 July 2024

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment70
Start date1 August 2023
Primary completion1 July 2024
Estimated completion1 July 2024
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

18 and older, any sex, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Following the major technological and scientific advances in external radiotherapy in recent decades, thanks to the use of three-dimensional conformal techniques combined with intensity modulation, image-guided radiotherapy has enabled radiotherapists to increase doses without increasing sequelae and complications, giving rise to the term "dose escalation". Following multiple dose-escalation clinical trials showing better biological control of PSA, the results of the latest phase 3 FLAME trial incorporated the notion of intraprostatic boost in relation to the primary prostate lesion, considered to be the preferred site of neoplastic recurrence in prostate cancer. This leads to the first question, which concerns the identification of the dominant lesion and its precise delimitation. This last point is subject to variation between operators. A retrospective cohort from the Finistère region will therefore be used to develop a number of study points relating to : inter-operator contour variability * Factors influencing contour * Impact of contour variability on dosimetry * Automatic segmentation

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Inter-Rater Variability of Prostate Lesion Segmentation on Multiparametric Prostate MRI.
    Jeganathan T, Salgues E, Schick U, Tissot V, et al · · 2023 · cited 7× · PMID 38137530 · DOI 10.3390/biomedicines11123309

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05996289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing